Triple threat: new combo tackles rare lung cancer

NCT ID NCT05765084

Recruiting now Disease control Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether adding an immunotherapy drug (atezolizumab) and a personalized vaccine (WT1/DC) to standard chemotherapy can safely improve outcomes for people with a rare type of mesothelioma. The study plans to enroll 15 adults with epithelioid malignant pleural mesothelioma that cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors or slows the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (PD-L1 inhibitor) and WT1/DC vaccine (dendritic cells loaded with WT1 protein)
What this could lead to: If successful, this could lead to a new first-line treatment option that improves tumor response and survival for people with epithelioid malignant pleural mesothelioma.
What could go wrong: This is a very early, small trial (15 people) focused on safety and feasibility. The combination may cause significant side effects or fail to show meaningful clinical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIOID MALIGNANT PLEURAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma Mesothelioma, Malignant pleural epithelioid mesothelioma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PLEURAL MESOTHELIOMA

Contacts and locations

Locations

AZ Maria Middelares
RECRUITING

Ghent, 9000, Belgium
Antwerp University Hospital
RECRUITING

Edegem, Antwerp, 2650, Belgium
VITAZ
RECRUITING

Sint-Niklaas, 9100, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.